

# Caroline Gordon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2991074/caroline-gordon-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

15,295  
citations

57  
h-index

121  
g-index

229  
ext. papers

18,937  
ext. citations

5.2  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
200	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
199	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 222-33		866
198	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1771-82	2.4	692
197	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 736-745	2.4	628
196	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 809-13		505
195	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16039	51.1	422
194	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 958-67	2.4	388
193	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, 209	5.7	373
192	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. <i>Arthritis Research and Therapy</i> , <b>2005</b> , 7, R784-95	5.7	332
191	The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. <i>Arthritis and Rheumatism</i> , <b>1995</b> , 38, 551-8		286
190	Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 369-78	9.5	262
189	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. <i>Rheumatology</i> , <b>2016</b> , 55, 1693-7	3.9	251
188	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
187	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2005</b> , 19, 685-708	5.3	217
186	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
185	The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 357-68	9.5	205
184	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 183-90	2.4	205

183	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 191-5	6.1	198
182	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
181	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2006-15	2.4	189
180	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 972-9		185
179	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175
178	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , <b>2018</b> , 57, e1-e45	3.9	150
177	Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , <b>2009</b> , 48, 1451-4	3.9	144
176	Ocular manifestations of systemic lupus erythematosus. <i>Rheumatology</i> , <b>2007</b> , 46, 1757-62	3.9	144
175	Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. <i>Clinical Immunology and Immunopathology</i> , <b>1989</b> , 52, 421-34		134
174	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 362-375	9.5	125
173	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , <b>2011</b> , 50, 982-8	3.9	120
172	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
171	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 211-21		106
170	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , <b>2013</b> , 52, 1313-22	3.9	98
169	Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 231-8	4.1	95
168	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. <i>Rheumatology</i> , <b>2016</b> , 55, 1698-702	3.9	93
167	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , <b>2011</b> , 50, 657-64	3.9	91
166	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , <b>2010</b> , 49, 1665-9	3.9	84

165	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
164	Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. <i>Rheumatology</i> , <b>2009</b> , 48, 1506-11	3.9	83
163	Systemic lupus erythematosus: clinical presentations. <i>Autoimmunity Reviews</i> , <b>2010</b> , 10, 43-5	13.6	82
162	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 892-9		81
161	The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1996-2005	9.5	80
160	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2006-2017	9.5	78
159	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
158	Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3300-5		77
157	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 4113-9		76
156	Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 2494-502	9.5	75
155	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , <b>2009</b> , 48, 691-5	3.9	74
154	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 904-13	4.3	71
153	Primary anti-phospholipid antibody syndrome (APS): current concepts. <i>Survey of Ophthalmology</i> , <b>2002</b> , 47, 215-38	6.1	70
152	Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R120	5.7	69
151	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
150	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
149	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 322-9	4.1	65
148	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. <i>Rheumatology</i> , <b>2015</b> , 54, 836-43	3.9	64

147	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , <b>2010</b> , 49, 723-32	3.9	63
146	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. <i>Rheumatology</i> , <b>2013</b> , 52, 2292-301	3.9	58
145	Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1776-86		58
144	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , <b>2016</b> , 55, 957-67	3.9	57
143	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , <b>2014</b> , 53, 275-84	3.9	57
142	Causes and management of infertility in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2011</b> , 50, 1551-8	3.9	54
141	The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 1410-8		54
140	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. <i>Rheumatology</i> , <b>2014</b> , 53, 502-11	3.9	53
139	Biologic therapy and pregnancy outcomes in women with rheumatic diseases. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 587-92		52
138	Pregnancy and rheumatic diseases. <i>Rheumatology</i> , <b>2007</b> , 46, 1634-40	3.9	52
137	Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 398	4.1	51
136	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
135	The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 64-70		51
134	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1784-8		49
133	Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. <i>BMJ Open</i> , <b>2014</b> , 4, e004081	3	48
132	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , <b>2018</b> , 57, 470-4	3.9	47
131	Population-based lupus registries: advancing our epidemiologic understanding. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1462-6		47
130	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46

129	The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 2273-9	4.1	44
128	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1167-76	4.7	43
127	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2004</b> , 18, 359-39	3.9	40
126	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , <b>2010</b> , 1, 163-75	4.9	39
125	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1505-13	4.7	38
124	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
123	In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 759-66	4.7	36
122	Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. <i>Rheumatology</i> , <b>2008</b> , 47, 334-8	3.9	35
121	Managing pregnancy in inflammatory rheumatological diseases. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, 206	5.7	34
120	Quality of life and economic evaluation in SLE clinical trials. <i>Lupus</i> , <b>1999</b> , 8, 645-54	2.6	34
119	Interferon- $\beta$ -induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erythematosus monocytes. <i>Rheumatology</i> , <b>2014</b> , 53, 2249-58	3.9	32
118	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 128-35	4.7	31
117	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 763-773	9.5	31
116	B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. <i>BioDrugs</i> , <b>2013</b> , 27, 85-95	7.9	31
115	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , <b>2009</b> , 48, 1548-52	3.9	31
114	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 470-6	2.4	31
113	Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 457-67	5.3	31
112	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31

111	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 2390-4	4.1	31
110	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1068-72	4.7	28
109	Systemic lupus and malignancies. <i>Current Opinion in Rheumatology</i> , <b>2012</b> , 24, 177-81	5.3	28
108	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
107	Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Ataccept and Serum Biomarkers Including BlyS and APRIL. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 122-130	9.5	26
106	Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus - Fulton and DeKalb Counties, Georgia, 2002-2016. <i>Morbidity and Mortality Weekly Report</i> , <b>2019</b> , 68, 419-422	31.7	26
105	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 991-996	9.5	25
104	Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program. <i>American Journal of Public Health</i> , <b>2015</b> , 105, e74-9	5.1	24
103	Mycophenolate mofetil for remission induction in severe lupus nephritis. <i>Nephron Clinical Practice</i> , <b>2005</b> , 100, c92-100		24
102	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
101	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , <b>2018</b> , 57, 14-18	3.9	23
100	Challenges of ethnicity in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 549-61	5.3	23
99	Update on systemic lupus erythematosus: autoantibodies and apoptosis. <i>Clinical Medicine</i> , <b>2001</b> , 1, 10-4	1.9	23
98	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. <i>Rheumatology</i> , <b>2012</b> , 51, 1877-80	3.9	22
97	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , <b>2013</b> , 13, 405-412	5.2	22
96	Systemic lupus erythematosus in women: impact on family size. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 1656-60		22
95	Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 357-65	4.7	22
94	Advances in the assessment of lupus disease activity and damage. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 510-9	5.3	21

93	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , <b>2019</b> , 9, e032569	3	21
92	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
91	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	21
90	Systemic lupus erythematosus: An update for ophthalmologists. <i>Survey of Ophthalmology</i> , <b>2016</b> , 61, 65-82	2.1	20
89	Stratifying management of rheumatic disease for pregnancy and breastfeeding. <i>Nature Reviews Rheumatology</i> , <b>2019</b> , 15, 391-402	8.1	20
88	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
87	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 729-735	2.4	20
86	Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 95-103	4.7	20
85	Epratuzumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 245-258	5.1	19
84	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 949-960	4.7	19
83	Systemic lupus erythematosus and malignancies: a review article. <i>Rheumatic Disease Clinics of North America</i> , <b>2014</b> , 40, 497-506, viii	2.4	19
82	Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 874-881	4.7	19
81	A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves disease: Comment on the article by Rood et al. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 3109-10		18
80	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
79	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
78	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 875-80	4.1	17
77	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
76	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000034	4.6	15



75	Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1789-95		15
74	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
73	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2013</b> , 3,	3	14
72	Novel treatments for systemic lupus erythematosus. <i>Current Opinion in Investigational Drugs</i> , <b>2010</b> , 11, 1256-64		14
71	The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 263-71	3.9	13
70	Refractory multisystem sarcoidosis responding to infliximab therapy. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 1013-8	3.9	13
69	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13
68	Pregnancy and autoimmune diseases <b>2004</b> , 18, 359-359		12
67	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa006	1.1	11
66	The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , <b>2012</b> , 51, 2099-105	3.9	11
65	The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkaa072	1.1	11
64	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
63	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
62	From BILAG to BILAG-based combined lupus assessment-30 years on. <i>Rheumatology</i> , <b>2016</b> , 55, 1357-63	3.9	9
61	Is it me? The impact of patient-physician interactions on lupus patients' psychological well-being, cognition and health-care-seeking behaviour. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa037	1.1	9
60	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000344	4.6	8
59	Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1271-1275	4.7	8
58	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> ,	8	8

57	Telemedicine in rheumatology: A mixed methods study exploring acceptability, preferences and experiences among patients and clinicians. <i>Rheumatology</i> , <b>2021</b> ,	3.9	8
56	Medications in pregnancy and breastfeeding. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2020</b> , 64, 68-76	4.6	8
55	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
54	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
53	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , <b>2018</b> , 57, 1502-1503	3.9	7
52	Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline. <i>Musculoskeletal Care</i> , <b>2009</b> , 7, 210-8	1.6	7
51	Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2009</b> , 5, 27-34	5.1	7
50	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
49	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
48	Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease. <i>Drugs</i> , <b>1994</b> , 47, 259-85	12.1	6
47	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE-data from the BSR audit of systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 1474-1479	3.9	6
46	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
45	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. <i>Immunotherapy</i> , <b>2014</b> , 6, 1165-75	3.8	5
44	Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015. <i>Morbidity and Mortality Weekly Report</i> , <b>2019</b> , 68, 819-824	31.7	5
43	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
42	Cancer and Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2020</b> , 46, 533-550.	4	4
41	Lupus and zoster. <i>Lancet, The</i> , <b>2003</b> , 362, 616	4.0	4
40	Factors involved in the pathogenesis of neutrophilic vasculitis in MRL/Mp-lpr/lpr mice: a model for human microscopic angiitis. <i>Autoimmunity</i> , <b>1999</b> , 31, 133-45	3	4

39	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b>	2.4	4
38	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
37	Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. <i>Trials</i> , <b>2020</b> , 21, 652	2.8	3
36	But you don't look sick! A qualitative analysis of the LUPUS UK online forum. <i>Rheumatology International</i> , <b>2021</b> , 41, 721-732	3.6	3
35	COVID-19 and shielding: experiences of UK patients with lupus and related diseases. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab003	1.1	3
34	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz021	1.1	2
33	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 3262-3267	3.9	2
32	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
31	Mortality in SLE <b>2013</b> , 666-675		2
30	Large vessel vasculitides. <i>Medicine</i> , <b>2006</b> , 34, 468-471	0.6	2
29	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
28	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
27	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
26	Medication decision-making and adherence in lupus: Patient-physician discordance and the impact of previous Adverse Medical Experiences <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
25	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , <b>2021</b> , 60, 1480-1490	3.9	2
24	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , <b>2017</b> , 56, 1041-1043	3.9	1
23	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 287	5.7	1
22	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2343-4		1

21	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 569-70	2.4	1
20	Will the feeling of abandonment remain? Persisting impacts of the Covid-19 pandemic on rheumatology patients and clinicians. <i>Rheumatology</i> , <b>2022</b> ,	3.9	1
19	Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1561-1567	4.7	1
18	Constitutional Symptoms and Fatigue in Systemic Lupus Erythematosus <b>2016</b> , 317-324		1
17	Prescribing anti-rheumatic drugs in pregnancy and breastfeeding-the British Society for Rheumatology guideline scope. <i>Rheumatology</i> , <b>2021</b> , 60, 3565-3569	3.9	0
16	Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. <i>Lupus</i> , <b>2021</b> , 30, 1492-1501	2.6	0
15	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 203	5.7	0
14	Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review. <i>Lupus</i> , <b>2021</b> , 9612033211050337	2.6	0
13	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9, e000584	4.6	0
12	Obituary for Paul Bacon. <i>Rheumatology</i> , <b>2018</b> , 57, 943-945	3.9	
11	Rheumatic Disease <b>2013</b> , 1415-1440		
10	Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 1391-2	4.7	
9	Malignancies in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , <b>2013</b> , 8, 275-280	1.5	
8	Rheumatoid Arthritis/SLE267-281		
7	Constitutional Features of Systemic Lupus Erythematosus <b>2007</b> , 329-335		
6	Fertility and pregnancy in autoimmune rheumatic diseases. <i>Indian Journal of Rheumatology</i> , <b>2016</b> , 11, 115	0.5	
5	Co-morbidities in Systemic Lupus Erythematosus <b>2012</b> , 229-249		
4	Malignancies in Systemic Lupus Erythematosus <b>2016</b> , 411-415		

- 3 Constitutional symptoms and fatigue in systemic lupus erythematosus **2021**, 351-359
- 2 Malignancies in systemic lupus erythematosus **2021**, 461-467
- 1 Malignancy risk and screening **2021**, 583-598